Navigation Links
BHR Pharma Statement on Brain Injury Awareness Month - Better Awareness, Treatment, Research Needed Now

HERNDON, Va., March 23 /PRNewswire-USNewswire/ -- Julian Bailes, MD, BHR Pharma, LLC's Lead Advisor for Moderate Traumatic Brain Injury (TBI) today released the following statement regarding Brain Injury Awareness Month:

"BHR Pharma salutes the Brain Injury Association of America (BIAA) for its concerted efforts to raise awareness about the dangers and proper treatment of concussions everywhere from playgrounds to professional sports arenas.  BIAA is correctly pointing out through its advocacy that concussions are TBIs, with the potential for serious, debilitating and long-term effects.  

"TBI is defined as a non-degenerative, non-congenital insult to the brain from an external mechanical force, possibly leading to temporary or permanent impairments of cognitive, physical and psychosocial functions with an associated diminished or altered state of consciousness.

"According to the Centers for Disease Control and Prevention, U.S. hospital emergency departments treat an estimated 3.8 million sports- and recreation-related concussions annually.  It is time that athletes of all ages and their coaches completely move away from 'play through pain' attitudes in relation to concussions.  

"During Brain Injury Awareness Month, it is also important to recognize that traumatic brain injuries range from concussions to severe head trauma, such as injuries sustained in traffic accidents – a leading cause of TBI in the world, accounting for 40-50 percent of hospitalizations.  Approximately 1.7 million Americans per year suffer a traumatic brain injury, resulting in 52,000 deaths, 275,000 hospitalizations and 80,000 cases of long-term disability.

"Although the prognosis for patients that are hospitalized with a severe form of TBI is generally not very promising, current research is pointing to a future of treatment that potentially offers these patients and their families hope for better quality of life.  In particular, two multi-center, Phase 3 clinical trials are worth noting.  They are BHR Pharma's SyNAPSe ( and Emory University's ProTECT III ( trials.  Both are evaluating the safety and effectiveness of progesterone as a neuroprotective agent for treating moderate to severe TBI.

"The success of these studies requires that study staff quickly reach family members to request permission to enroll their loved one in the trial. Although it may occur at a time of great personal pain and confusion, the families' difficult decision-making – usually in an emergency room setting – will go a long way in helping advance TBI treatment."


Back to top



Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Drug Information Association (DIA) Announces New Clinical Safety and Pharmacovigilance Certificate Program
2. Huifeng Bio-Pharmaceutical Provides Preliminary 2009 Financial Results and 2010 Guidance
3. Octapharma Accepting Applications for Research Grants Through March 31
4. Two Long-Term Care Organizations Select Remedi SeniorCare for Pharmacy Services
5. Possible pharmacological target(s) identified in pediatric OSA
6. Therapure Biopharma Inc. and Akorn, Inc. Announce Strategic Supply Contract
7. Six Key Areas of Learning for Pharmaceutical and Healthcare Marketing in 2010
8. Frost & Sullivan Ghanaian Pharmaceutical Industry Innovation & Advancement Award Conferred on LaGray Chemical Company
9. Viscira Expands Interactive Solutions to Reduce Marketing Expenses for Pharmaceutical Companies in Challenging Economic Times
10. Nutra Pharma Announces Fourth Quarter Sales for its Over-the-Counter (OTC) Pain Reliever, Cobroxin
11. Pharmalink Regulatory Affairs Consulting Firm Opens New Offices in Washington, DC and Hartford, CT
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... “Women have 2 questions when they ... to live?’ The second is, “Will I lose my hair?’” , Carly Klein is ... women with licensed medical professionals to develop personalized hair loss treatment plans. With 10 ...
(Date:10/13/2015)... — , ... ... Association of America (MOAA) will hold its 2015 annual meeting ... a free military career fair; informational seminars; a luncheon featuring ... the Joint Chiefs of Staff; and the Community Heroes Award ...
(Date:10/13/2015)... ... ... The American Institutes for Research ( AIR ) developed a collection of guides ... sexual assault and other trauma. The toolkit, funded by the U.S. Department of Education, ... 21st anniversary. , AIR developed the Safe Place toolkit in ...
(Date:10/13/2015)... ... 13, 2015 , ... "My friend's son suffers from eczema, and he had ... an inventor from Platteville, Colo. "I came up with this kit as a way ... to prevent a child from rubbing or scratching his or her face. This protects ...
(Date:10/13/2015)... , ... October 13, 2015 , ... According to an ... recent study has shown that women who successfully lose weight with a bariatric procedure ... United States each year. The article notes that anywhere from 40 to 50 percent ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... , Oct. 13, 2015   Vigilant Biosciences, ... solutions that aid in the early detection and intervention ... awarded Vigilant,s founder and CEO, Matthew H.J. Kim ... Award, which recognizes an entrepreneur who has made extraordinary ... life sciences industry in the leadership of a ...
(Date:10/13/2015)... , Oct. 13, 2015   ... first-ever direct-to-consumer laboratory home testing kit for ... digital technologies provide an unparalleled, detailed assessment ... breast milk—fats, proteins, carbs and key vitamins—all ... portal for personal health tracking.  In addition, Happy ...
(Date:10/13/2015)... , October 13, 2015 ... announced the appointment of Harry Lander , PhD as ... Company,s Chairman & CEO David Koos as Regen ... molecule and immuno-oncological therapeutics. --> Regen BioPharma, ... appointment of Harry Lander , PhD as its new ...
Breaking Medicine Technology: